Castle Biosciences
360Dx Top 30 Ticks up 2 Percent in August
Of the 30 companies in the index, 17 saw their share price increase, 12 saw their stock price decline, and one remained flat month over month.
Castle Biosciences Q2 Revenues Jump 74 Percent
The firm saw particularly high volume growth for its newer tests, including assays for Barrett's esophagus and IDgenetix, its recently acquired PGx assay.
Palmetto Declines to Cover Molecular Risk Stratification Tests for Cutaneous Squamous Cell Carcinoma
The three other Medicare administrative contractors that participate in the MolDx program aligned their coverage with Palmetto's.
360Dx Top 30 Rises 3 Percent in March
Of the 30 companies in the index, 18 companies saw their share prices rise in March, while 12 firms saw their share prices decline.
Castle Biosciences Squamous Cell Cancer Test Utility Boosted by New Validation Data, Expert Opinion
Premium
Updated validation data for the DecisionDx-SCC test was published earlier this month, followed by an opinion paper offering consensus guidelines for clinical use.
Mar 1, 2024
360Dx Top 30 Creeps up 1 Percent in February
Sep 1, 2023
360Dx Top 30 Ticks Down in August
Jul 5, 2023